Silence Therapeutics to buy Intradigm through share-swap deal

12/16/2009 | Reuters

The U.K.'s Silence Therapeutics agreed to issue 79.64 million shares to acquire Intradigm, a California biotech firm, to boost its presence in RNAi treatments. Silence Chairman Iain Ross said he hopes the merger will help the firm secure a major partnership with a drugmaker next year.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Principal Engineer - Service (US/MI/00/0043/SL) - 14000009CP
Abbott
Chicago, IL
Senior Manager, Compliance
Stryker
Fremont, CA
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA